A组溶血性链球菌抗DNA酶B抗体检测的临床应用价值探讨

应用微量法检测抗DNA酶B ,以探索其在A组溶血性链球菌感染所致疾病中的临床应用价值 ,同时用乳胶凝集法检测抗链球菌溶血素O (ASO)。结果显示 :风心组、急性肾小球肾炎组抗DNA酶B阳性率分别为 86 .5 %和 90 .7% ,显著高于ASO阳性率 5 1.9%、5 5 .8% (P <0 .0 5 )。而两者联合检测阳性率在 90 %以上。风湿热组、咽炎扁桃体炎组抗DNA酶B阳性率分别为 73 .5 %和 2 8.8% ,虽和ASO (6 7.6 % ,38.5 % )差异无显著性 (P >0 .0 5 ) ,但两者联合检测阳性率可达88.2 %和 5 7.7%。提示抗DNA酶B对急性肾小球肾炎、风湿热、风心病的诊断有重要的临床价值。ASO联合抗DNA酶B检测可提高A组溶血性链球菌的检出率 ,两者有重要的互补作用

Clinical value of the detection of anti-DNase B antibody in Group A hemolytic Streptococcus

In order to evaluate the role of anti-deoxyribonuclease B (anti-DNase B) in diseases induced by Group A hemolytic Streptococcus (GAS) infection, anti-DNase B antibody was detected by using the micromethod and at the same time antistreptolysin 0 (ASO) was also tested by using the latex agglutination method. Results showed that the positive rates of anti-DNase B in the rheumatic heart disease group and the acute glomerulonephritis group were 86.5% and 90.7%, respectively. Both of them were significantly higher than the positive rates of ASO (51.9% and 55.8%, respectively, P<0.05), but the positive rate was over 90% by using the two methods together. In the rheumatic fever group, and the pharyngitis and tonsillitis group, the positive rates of anti-DNase B were 73.5% and 28.8%, respectively, and they were almost the same in comparison with the rates of ASO, 67.6% and 38.5%, respectively. There was no statistical difference (P>0.05), but the positive rates could reach 88.2% and 57.7% by using the two methods together. This study suggests that detection of the anti-DNase B have great clinical value in the diagnosis of acute glomerulonephritis, rheumatic fever and rheumatic heart disease. GAS can be identified more easily by the detection of ASO in combination with anti-DNase B (And this combination can increase the detectable rate of GAS).